reports
- Carole Braudeau
- Carole Braudeau
- Chaima Ferrandon
- Sven Edelfelt
- Carole Braudeau
- Chaima Ferrandon
- Sven Edelfelt
- Carole Braudeau
- Manuel Martin
- CEFA
- CREA
- Carole Braudeau
- Carole Braudeau
- Manuel Martin
- CEFA
- CREA
- Manuel Martin
- CEFA
- CREA
- Manuel Martin
- CEFA
- CREA
- Ghada Ben Sedrine
- Nicolas David
- Ghada Ben Sedrine
- Nicolas David
- Ghada Ben Sedrine
- Nicolas David
- Ghada Ben Sedrine
- Nicolas David
- Adrian Pehl
ISS ISS A/S
VLS VALNEVA SE
NOEJ NORMA GROUP SE
ROS ROSENBAUER INTERNATIONAL AG
INH INDUS HOLDING AG
TEG TAG IMMOBILIEN AG
COK CANCOM SE
TECN TECAN GROUP AG
TWEKA TKH GROUP N.V. CERT
JUN3 JUNGHEINRICH AG PREF
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
AEIN ALLGEIER HOLDING AG
FQT FREQUENTIS AG WIENER
ALLFG ALLFUNDS (UK) LTD
SCHOTT PHARMA AG
- Adrian Pehl
ISS ISS A/S
VLS VALNEVA SE
NOEJ NORMA GROUP SE
ROS ROSENBAUER INTERNATIONAL AG
INH INDUS HOLDING AG
TEG TAG IMMOBILIEN AG
COK CANCOM SE
TECN TECAN GROUP AG
TWEKA TKH GROUP N.V. CERT
JUN3 JUNGHEINRICH AG PREF
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
AEIN ALLGEIER HOLDING AG
FQT FREQUENTIS AG WIENER
ALLFG ALLFUNDS (UK) LTD
SCHOTT PHARMA AG
- Manuel Martin
- CEFA
- CREA
- Tijs Hollestelle
BAM/Time to take its valuation out of second division/BUY
We maintain our BUY rating and raise our target price from €5.90 to €9.00 per share. We increase our FY25F and FY26F EPS estimates by 13% and 9% respectively following better-than-expected 1H25 results and a slightly higher FY25 adjusted EBITDA margin outlook. We use a new 10.5x target PER to back our new €9.00 target price and move to our FY26F EPS. Previously we valued BAM using the stock's long-term historical mid-cycle multiple of 8.5x and now take the high end of the multiple trading range ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.